@article{TAU14174,
author = {Jason Gandhi and Steven J. Weissbart and Noel L. Smith and Steven A. Kaplan and Gautam Dagur and Anna Zumbo and Gargi Joshi and Sardar Ali Khan},
title = {The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia},
journal = {Translational Andrology and Urology},
volume = {6},
number = {2},
year = {2017},
keywords = {},
abstract = {Benign prostatic hyperplasia (BPH) is one of the most common genitourinary complications in men over 50 years of age and typically presents with lower urinary tract symptoms (LUTS). Classes of medications include α1-adrenoceptor blockers, 5α-reductase inhibitors, and phosphodiesterase 5 inhibitors. Today, α1-adrenoceptor blockers and 5α-reductase inhibitors are often combined to give a synergistic effect. A review of the current literature identified several adverse sexual side effects, including erectile dysfunction (ED), decreased libido, orgasmic disorders, and ejaculatory disorders. We believe it is important to know the extent of these side effects, as the clinician and patient will need to decide the cost of improved voiding symptoms. The chief adverse effect is ejaculatory disorders, including the absence of ejaculation. Clinical consideration for BPH should include the elements of male sexual function, patients’ age, and the characteristics and comprehensive effects of each group of drugs. Methodological bias in clinical studies, such as the subjective evaluation of the sexual side effect, makes it difficult to determine the ideal drug for treatment.},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/14174}
}